Repaglinide Pregnancy and Breastfeeding Warnings
Repaglinide is also known as: Prandin
Repaglinide Pregnancy Warnings
AU: Use is contraindicated UK: Use should be avoided US: Use only if clearly needed AU TGA pregnancy category: C US FDA pregnancy category: C
Animal studies in rats have shown nonteratogenic skeletal deformities consisting of shortening, thickening, and bending of the humerus when dams received 15 times expected clinical exposure on days 17 to 22 of gestation and during lactation. Teratogenicity was not observed in rats or rabbits exposed to doses of 40 times and 0.8 times expected human exposure, respectively, throughout pregnancy. In humans, abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Most experts recommend insulin use during pregnancy to maintain blood glucose levels. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Repaglinide Breastfeeding Warnings
Measurable levels of this drug have been detected in the breast milk of rats resulting in lowered blood glucose levels in the pups. There is no information available on its excretion in human milk.
AU: Use is contraindicated UK: Use is not recommended US: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: Blood glucose concentrations should be monitored in the breastfed infant.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.